title: Risk assessment in the management of patients with ocular hypertension.
abstract: OBJECTIVE
  To develop a model for estimating the global risk of disease progression in patients with ocular hypertension and to calculate the "number-needed-to-treat" (NNT) to prevent progression to blindness as an aid to practitioners in clinical decision making.
  
  
  METHODS
  Development of a mathematical model for estimating risk of glaucoma progression.
  
  
  METHODS
  Population-based studies of patients with ocular hypertension and glaucoma were reviewed by a panel of glaucoma specialists. Measures of disease progression risks derived from three long-term studies and assumptions based on the available data were used to estimate the risk of progression from ocular hypertension to glaucoma and glaucoma to unilateral blindness for untreated and treated patients over a 15-year period. Using these estimates, the NNT (1/absolute risk reduction on treatment) to prevent unilateral blindness in one patient with ocular hypertension was calculated.
  
  
  RESULTS
  In untreated patients, the estimated risk of progression from ocular hypertension to unilateral blindness was 1.5% to 10.5% and in treated patients, the estimated risk of progression was 0.3% to 2.4% over 15 years. From these estimates, between 12 and 83 patients with ocular hypertension will require treatment to prevent one patient from progressing to unilateral blindness over a 15-year period.
  
  
  CONCLUSIONS
  Global risk assessment that incorporates all available data plays a vital role in managing patients with ocular hypertension. A more precise understanding of long-term vision loss should be factored into decisions pertaining to the initiation of glaucoma therapy. Undoubtedly, these estimates will evolve and change with the availability of new population-based epidemiologic information and improvements in multivariable model testing.
authors.affiliation: Hamilton Glaucoma Center, University of California-San Diego, La Jolla, CA 92093-0946, USA. weinreb@eyecenter.ucsd.edu
authors.forename: Robert N
authors.initials: RN
authors.lastname: Weinreb
authors.forename: David S
authors.initials: DS
authors.lastname: Friedman
authors.forename: Robert D
authors.initials: RD
authors.lastname: Fechtner
authors.forename: George A
authors.initials: GA
authors.lastname: Cioffi
authors.forename: Anne L
authors.initials: AL
authors.lastname: Coleman
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Girkin
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Liebmann
authors.forename: Kuldev
authors.initials: K
authors.lastname: Singh
authors.forename: M Roy
authors.initials: MR
authors.lastname: Wilson
authors.forename: Richard
authors.initials: R
authors.lastname: Wilson
authors.forename: William B
authors.initials: WB
authors.lastname: Kannel
mesh_terms: D001766:Blindness / Q000209:etiology / Q000517:prevention & control; D003657:Decision Making; D018450:Disease Progression; D005901:Glaucoma / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008954:Models, Biological; D008962:Models, Theoretical; D009798:Ocular Hypertension / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors